Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Recommendation is based on the Phase III IMpower110 study showing that Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy If approved, Tecentriq could offer people with a specific type of lung cancer a chemotherapy-free option in the first-line treatment setting Basel, 26 March 2021 – Roche (SIX: RO, ROG;... Read more